hypoxia-activated FLT3 inhibitor prodrug (MD Anderson Cancer Center/University of Auckland)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namehypoxia-activated FLT3 inhibitor prodrug (MD Anderson Cancer Center/University of Auckland)
Drug Alias NameSN-37169
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of AucklandThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A